BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29850793)

  • 41. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
    Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
    Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Elevated Oxidative Stress Impairs Hematopoietic Progenitor Function in C57BL/6 Substrains.
    Morales-Hernández A; Martinat A; Chabot A; Kang G; McKinney-Freeman S
    Stem Cell Reports; 2018 Aug; 11(2):334-347. PubMed ID: 30017822
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Loss of
    Williams JL; Hall CL; Meimaridou E; Metherell LA
    Int J Mol Sci; 2021 Jun; 22(11):. PubMed ID: 34198873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LncRNA NNT-AS1 regulates the progression of lung cancer through the NNT-AS1/miR-3666/E2F2 axis.
    Huang JW; Luo XY; Li ZH; Lang BP
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):238-248. PubMed ID: 31957837
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Silencing long non-coding RNAs nicotinamide nucleotide transhydrogenase antisense RNA 1 inhibited papillary thyroid cancer cell proliferation, migration and invasion and promoted apoptosis via targeting miR-199a-5p.
    Wang D; Zheng Y
    Endocr J; 2021 May; 68(5):583-597. PubMed ID: 33612561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nicotinamide nucleotide transhydrogenase mutation analysis in Chinese patients with thyroid dysgenesis.
    Li M; Tian W; Wang F; Yang C; Zhang L; Tang Q; Liu S; Wang F
    Am J Med Genet A; 2022 Jan; 188(1):89-98. PubMed ID: 34545694
    [TBL] [Abstract][Full Text] [Related]  

  • 47. MicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma.
    Glover AR; Zhao JT; Gill AJ; Weiss J; Mugridge N; Kim E; Feeney AL; Ip JC; Reid G; Clarke S; Soon PS; Robinson BG; Brahmbhatt H; MacDiarmid JA; Sidhu SB
    Oncotarget; 2015 Nov; 6(34):36675-88. PubMed ID: 26452132
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
    Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel homozygous insertion and review of published mutations in the NNT gene causing familial glucocorticoid deficiency (FGD).
    Jazayeri O; Liu X; van Diemen CC; Bakker-van Waarde WM; Sikkema-Raddatz B; Sinke RJ; Zhang J; van Ravenswaaij-Arts CM
    Eur J Med Genet; 2015 Dec; 58(12):642-9. PubMed ID: 26548497
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hescot S; Paci A; Seck A; Slama A; Viengchareun S; Trabado S; Brailly-Tabard S; Al Ghuzlan A; Young J; Baudin E; Lombès M
    Horm Cancer; 2014 Oct; 5(5):312-23. PubMed ID: 25026941
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PERSONALIZED CARE OF PATIENTS WITH ADRENOCORTICAL CARCINOMA: A COMPREHENSIVE APPROACH.
    Miller BS; Else T;
    Endocr Pract; 2017 Jun; 23(6):705-715. PubMed ID: 28614035
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nicotinamide nucleotide transhydrogenase activity impacts mitochondrial redox balance and the development of hypertension in mice.
    Leskov I; Neville A; Shen X; Pardue S; Kevil CG; Granger DN; Krzywanski DM
    J Am Soc Hypertens; 2017 Feb; 11(2):110-121. PubMed ID: 28087333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
    Ren L; Yang Y; Li W; Zheng X; Liu J; Li S; Yang H; Zhang Y; Ge B; Zhang S; Fu W; Dong D; Du G; Wang J
    J Transl Med; 2022 Oct; 20(1):444. PubMed ID: 36184616
    [TBL] [Abstract][Full Text] [Related]  

  • 54. STMN1 is Overexpressed in Adrenocortical Carcinoma and Promotes a More Aggressive Phenotype In Vitro.
    Aronova A; Min IM; Crowley MJP; Panjwani SJ; Finnerty BM; Scognamiglio T; Liu YF; Whitsett TG; Garg S; Demeure MJ; Elemento O; Zarnegar R; Fahey TJ
    Ann Surg Oncol; 2018 Mar; 25(3):792-800. PubMed ID: 29214451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
    Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
    J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples.
    Gara SK; Wang Y; Patel D; Liu-Chittenden Y; Jain M; Boufraqech M; Zhang L; Meltzer PS; Kebebew E
    Nucleic Acids Res; 2015 Oct; 43(19):9327-39. PubMed ID: 26446994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
    Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
    Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. FSCN1 as a new druggable target in adrenocortical carcinoma.
    Ruggiero C; Tamburello M; Rossini E; Zini S; Durand N; Cantini G; Cioppi F; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Landwehr LS; Weigand I; Kurlbaum M; Zizioli D; Turtoi A; Yang S; Berruti A; Luconi M; Sigala S; Lalli E
    Int J Cancer; 2023 Jul; 153(1):210-223. PubMed ID: 36971100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic and expression profiling of adrenocortical carcinoma: application to diagnosis, prognosis and treatment.
    Bussey KJ; Demeure MJ
    Future Oncol; 2009 Jun; 5(5):641-55. PubMed ID: 19519204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Caenorhabditis elegans mutant lacking functional nicotinamide nucleotide transhydrogenase displays increased sensitivity to oxidative stress.
    Arkblad EL; Tuck S; Pestov NB; Dmitriev RI; Kostina MB; Stenvall J; Tranberg M; Rydström J
    Free Radic Biol Med; 2005 Jun; 38(11):1518-25. PubMed ID: 15890626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.